Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Actelion
Biotech
Idorsi's Fabry drug fails to relieve pain in phase 3 test
Idorsia’s Fabry disease therapy “did exactly what we were expecting,” according to one executive—except relieve neuropathic pain.
Annalee Armstrong
Oct 11, 2021 8:39am
J&J multiple sclerosis hopeful tops Sanofi's Aubagio in phase 3
Sep 11, 2019 6:03pm
J&J's multiple sclerosis prospect beats Sanofi drug in phase 3
Jul 26, 2019 7:32am
Idorsia sheds surplus DMD therapy to Santhera
Nov 21, 2018 9:23am
J&J scraps phase 3 antibiotic program acquired in $30B takeover
Apr 17, 2018 9:22am
Sage expands into sleep disorders after early-phase success
Jan 31, 2018 9:50am
